Tag Archives: biomarkers

Enrichment design accommodating the biomarker misclassification

Increased understanding of the mechanistic heterogeneity of diseases has brought us to the era of molecularly targeted therapies (MTAs) in clinical oncology. The MTAs block the growth of cancer cells by identifying and attacking specific biomarker pathways

Finding aroma clues in the human breath to diagnose diseases

History of human odor analysis in disease diagnosis The use of the sense of smell as an indicator of human disease probably originated with Hippocrates (circa 400 BC). Early medical practitioners recognized that the presence of human

Secret of cardiovascular diseases (CVDs) hidden in small molecules

Diagnosis and treatment of cardiovascular diseases (CVDs) are a great challenge for today’s medicine. It also results from not fully explained pathomechanisms underlying their development and progression. The group of CVDs is a very complex mixture of

Replacement of saturated with unsaturated fats had no impact on vascular function but beneficial effects on lipid biomarkers and blood pressure

Disease of the heart and blood vessels (referred to as cardiovascular disease (CVD)) is the primary cause of death worldwide. A key public health recommendation for reducing the risk of developing CVD is to lower our intake of

Disregarded drivers of diversity within tumors

The past decades of cancer research have uncovered the staggering extent and widespread prevalence of intratumor heterogeneity, which refers to the differences between the genomes of cells in a tumor. In theory, each cancer arises from a

Spectroscopic platform to cut time and resources needed to quantify cancer cell biomarker concentrations

Survivability of a living cell, tissue and ultimately a being is influenced by the state of proteolytic degradation of extracellular matrix (ECM) components; if the dynamics of the degradation is perturbed, regulation of many biological processes such

CD64 as a sepsis marker

Sepsis is the most common cause of mortality in critically ill patients worldwide. Despite with huge costs, it is difficult to treat sepsis. Early diagnosis sepsis and timely treatment are vital to improving outcomes and lightening the

Highlighting inflammatory markers in anxiety disorders

Anxiety disorders, often originating early in life, are very common and effect 28.3% of the population. With this high prevalence comes an associated cost to the economy, mostly related to the extensive overuse of primary care services

New and future strategies for asthma control in children

Asthma continues to be a predominant health concern in children despite advances in medical care. Children are being diagnosed with asthma at earlier ages, and the adverse effects of early-onset, poorly controlled asthma can last throughout childhood

Making it easier to study personalized genomic biomarkers of lung disease

In the past few years, there has been significant progress in understanding how lung disease develops and predict who will respond to certain targeted therapies by obtaining lung tissue from research participants and studying changes in mechanistic

Glutathione: a molecular whistleblower for Alzheimer’s disease

Alzheimer’s disease: Neurons in select pockets of the brain begin to die off, slowly and incrementally erasing an individual’s memory and eroding their individuality. It is a devastating disease, one that affects more than 36 million individuals

Health benefits of haskap: Possible control of inflammation-mediated chronic disorders

Biologically active phytochemicals present in cool climate berries such as haskap (Lonicera caerulea L.) offer a great alternative therapy for mitigation of most of the chronic disorders. In general, polyphenols in fruits have shown the potential to

Blood-based biomarkers for multiple sclerosis

Multiple sclerosis (MS) is an immune-mediated, inflammatory demyelinating and neurodegenerative disease of the central nervous system (CNS). MS is classified in: relapsing–remitting (RRMS), characterized by acute attacks followed by partial or complete recovery periods; primary progressive (PPMS),